Table 5.
Serial observation 1 year after initial echocardiographic examination.
| Pre-diflunisal (n = 34) |
1 year after diflunisal | P | Treatment cessation due to newly developed renal dysfunction after diflunisal (n = 7) | Treatment cessation 1 year | P | |
|---|---|---|---|---|---|---|
| Age, year | 57 ± 16 | – | – | 54 ± 17 | – | – |
| Gender (M/F), n | 23/11 | – | – | 5/2 | – | – |
| V30M/non-V30M | 27/7 | – | – | 7/0 | – | – |
| Group 1/2/3 | 12/7/15 | – | – | 3/1/3 | ||
| SBP, mm Hg | 112 ± 14 | 111 ± 14 | 0.87 | 109 ± 11 | 111 ± 18 | 0.49 |
| DBP, mm Hg | 70 ± 12 | 69 ± 11 | 0.57 | 67 ± 5 | 72 ± 6 | 0.10 |
| Heart rate, bpm | 68 ± 11 | 64 ± 12 | 0.05 | 70 ± 8 | 73 ± 14 | 0.49 |
| BUN, mg/dl | 14.1 ± 4.9 | 15.8 ± 5.1 | 0.044 | 20.7 ± 9.0 | 24.1 ± 9.5 | 0.20 |
| Creatinine, mg/dl | 0.78 ± 0.21 | 0.83 ± 0.22 | 0.019 | 0.94 ± 0.35 | 0.95 ± 0.34 | 0.86 |
| IVSThd, cm | 1.59 ± 0.54 | 1.59 ± 0.53 | 0.94 | 1.75 ± 0.75 | 1.80 ± 0.64 | 0.58 |
| LVPWThd, cm | 1.33 ± 0.39 | 1.38 ± 0.41 | 0.16 | 1.49 ± 0.52 | 1.56 ± 0.51 | 0.12 |
| TMF-E/A | 1.15 ± 0.69 | 1.27 ± 0.68 | 0.18 | 1.69 ± 1.33 | 1.96 ± 2.1 | 0.54 |
| TMF-E-DT, ms | 235 ± 67 | 238 ± 68 | 0.79 | 188 ± 49 | 204 ± 50 | 0.62 |
| PVF-D/S | 0.98 ± 0.52 | 1.10 ± 0.62 | 0.08 | 1.69 ± 1.46 | 1.45 ± 0.97 | 0.54 |
| LVOT-VTI, cm | 20.2 ± 3.4 | 19.9 ± 3.4 | 0.65 | 15.5 ± 4.0 | 14.5 ± 3.4 | 0.44 |
| LVEDV, mL | 50 ± 16 | 49 ± 15 | 0.65 | 50 ± 8 | 40 ± 9 | 0.04 |
| LVESV, mL | 21 ± 8 | 20 ± 8 | 0.39 | 23 ± 8 | 20 ± 10 | 0.25 |
| LVEF, % | 60 ± 8 | 61 ± 7 | 0.43 | 55 ± 11 | 53 ± 16 | 0.46 |
| BNP, pg/mL | 123 ± 150 | 148 ± 156 | 0.13 | 200 ± 207 | 335 ± 365 | 0.26 |
| GLS (AFI), % | − 13.1 ± 3.8 | − 12.9 ± 4.0 | 0.45 | − 13.0 ± 6.2 | − 8.7 ± 5.4 | 0.07 |
| Mean basal LS, % | − 12.1 ± 5.8 | − 12.3 ± 5.6 | 0.52 | − 14.8 ± 7.1 | − 9.7 ± 5.4 | 0.07 |
| Mean mid LS, % | − 13.7 ± 4.3 | − 13.8 ± 4.2 | 0.90 | − 14.6 ± 6.0 | − 10.0 ± 5.0 | 0.052 |
| Mean apical LS, % | − 14.6 ± 3.4 | − 14.2 ± 3.3 | 0.55 | − 12.8 ± 4.8 | − 10.4 ± 4.3 | 0.29 |
| Basal GCS, % | − 16.6 ± 3.6 | − 17.1 ± 3.7 | 0.49 | − 17.1 ± 5.7 | − 16.4 ± 6.0 | 0.53 |
| Mid GCS, % | − 17.2 ± 3.6 | − 16.9 ± 3.9 | 0.68 | − 15.5 ± 6.2 | − 16.9 ± 6.7 | 0.22 |
| Apical GCS, % | − 17.9 ± 5.2 | − 18.7 ± 4.6 | 0.12 | − 18.5 ± 6.8 | − 16.6 ± 8.7 | 0.31 |
| Mean basal RS, % | 44 ± 21 | 40 ± 19 | 0.21 | 48 ± 25 | 37 ± 25 | 0.13 |
| Mean mid RS, % | 46 ± 21 | 43 ± 20 | 0.46 | 50 ± 28 | 34 ± 21 | 0.04 |
| Mean apical RS, % | 41 ± 20 | 37 ± 20 | 0.12 | 42 ± 28 | 32 ± 24 | 0.0077 |
| Basal LV rotation (°) | − 3.0 ± 3.7 | − 2.6 ± 4.2 | 0.68 | − 3.0 ± 2.4 | − 2.1 ± 2.8 | 0.52 |
| Apical LV rotation (°) | 4.8 ± 2.7 | 7.3 ± 3.6 | 0.0012 | 5.3 ± 4.4 | 8.7 ± 4.3 | 0.20 |
| LV torsion (°) | 7.5 ± 3.4 | 9.7 ± 5.1 | 0.037 | 8.4 ± 3.6 | 11.5 ± 4.9 | 0.18 |
No treatment, discontinued diflunisal because of deterioration in renal function after diflunisal treatment; IVSThd, LV thickness (septum); LVPWThd, LV thickness (posterior wall); TMF, transmitral flow; DT, deceleration time; PVF, pulmonary venous flow; LVOT, left ventricular outflow tract; VTI, velocity time integral; LVEDV, LV end-diastolic volume; LVESV, LV end-systolic volume; LVEF, LV ejection fraction; GLS, global longitudinal strain; AFI, automated function imaging; LS, longitudinal strain; GCS, global circumferential strain and RS, radial strain. Bold means statistically significance during 1 year follow-up.